Filing Overview
This Form 6-K was furnished by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, on October 25, 2023, covering October 2023 (Report No. 2). The filing relates to a Nasdaq listing compliance matter and does not provide financial statements or operating results.
The request metadata identifies the company as Newcelx Ltd.; however, the filing text identifies the registrant as NLS Pharmaceutics Ltd. Investors should verify the applicable issuer.
Material Event
- NLS Pharmaceutics announced receipt of a Nasdaq minimum bid price notification.
- The filing does not state the specific bid-price deficiency, the applicable compliance deadline, the company’s current share price, or the corrective actions being considered.
- The press release referenced as Exhibit 99.1 is not included in the provided filing text, so additional details cannot be confirmed.
Financial Information
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial metrics. No comparison with a prior period is available.
Risks and Contingencies
Failure to regain compliance with Nasdaq’s minimum bid price requirement could place the company’s listing at risk, subject to applicable Nasdaq procedures, deadlines, and any appeal or extension rights. The filing text does not clarify the potential timing or outcome.
Key Facts to Verify
- Obtain and review Exhibit 99.1 for the full terms of the Nasdaq notification.
- Confirm the minimum bid-price threshold, compliance period, deadline, and any available cure or appeal process.
- Determine whether the company has subsequently regained compliance or received additional Nasdaq notices.
- Verify the correct registrant, given the discrepancy between the request metadata and the filing text.